A glutamatergic deficiency model of schizophrenia

British Journal of Psychiatry

Volumn 174, Issue FEB. SUPPL. 37, 1999, Pages 2-6

  Carlsson, Arvid ^a   Hansson, L O ^b   Waters, N ^b   Carlsson, M L ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROTRANSMITTER RELEASE; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; THALAMUS; BRAIN CORTEX; METABOLISM;

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOGENIC AMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

BIOGENIC MONOAMINES; CEREBRAL CORTEX; DOPAMINE ANTAGONISTS; GLUTAMIC ACID; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0032988563     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000293574     Document Type: Review

References (21)

1. Andén, N.-E., Butcher, S. G., Corrodi, H., et al (1970) Receptor activity and turnover of dopamine and noradrenatine after neuroleptics. European Journal of Pharmacology, 11, 303-314.
2. Breier, A., Sue, T.-P., Saunders, R., et al (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America, 94, 2569-2574.
3. Carlsson, A. (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychophormacology, 1, 179-203.
4. _ & Lindqvist, M. (1963) Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine on mouse brain. Acta Pharmacologica et Toxicologica, 20, 140-144.
5. _ , Hansson, L. O., Waters, N., et al (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic applications. Life Sciences, 61, 75-94.
6. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse: implications for psychosis. Journal of Neural Transmission, 100, 225-237.
7. _ & Carlsson, A. (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. Journal of Neural Transmission, 75, 221-226.
8. Creese, I., Burt, D. R. & Snyder, S. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481-483.
9. Dao-Castellana, M.-H., Paillère-Martinot, M.-L., Hantraye, P., et al (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Research, 23, 167-174.
10. Hietala, J., Syvalahti, E., Vuorio, K., et al (1995) Presynaptic dopamine function in striatum of neuroleptic-naïve schizophrenic patients. Lancet, 346, 1130-1131.
11. Laruelle, M., Abi-Dargham, A., Gil, R., et al (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America, 18, 198.
12. Martin, P., Waters, N. R., Waters, S. E., et al (1997) MK-801 -induced hyperlocomotion: differential effects of MDL 100,907, SDZ PSD 958 and ractopride. European Journal of Pharmacology, 335, 107-116.
13. Miller, D. W. & Abercrombie, E. (1996) Effects of MK 801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Research Bulletin, 40, 57-62.
14. Nyback, H. & Sedvall, G. (1970) Further studies on the accumulation and disappearance of catecholamines formed from tyrosine-14-C in mouse brain. European Journal of Pharmacology, 10, 193-205.
15. 2A receptors in antipsychotic activity. Life Sciences, 56, 2209-2222.
16. Seeman, P., Lee, T., Chau-Wong, M., et al (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 261, 717-719.
17. Stille, G. (1976) Neurophysiological correlates to antipsychotic effects of drug. In Antipsychotic Drugs: Pharmacodynamics and Pharmacokinetics (eds F. Sedvall, B. Uvnas & Y. Zotterman), pp. 51-62. Oxford: Pergamon Press.
18. Svensson, A. & Carlsson, M. L. (1992) Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation. Neuropharmacology 31, 513-518.
19. Tamminga, C. A., Crayton, J. C. & Chase, T. N. (1978) Muscimol: GABA agonist therapy in schizophrenia. American Journal of Psychiatry, 135, 746-748.
20. Waters, N., Carlsson, A. & Hansson, L. (1994) An animal model of schizophrenia based on multivariate analysis of monoaminergic biochemistry and behaviour. Society of Neuroscience Abstracts, 20, 1, 825.
21. _ , _ & _ (1995) Evaluation of drug effects in a multivariate animal model of schizophrenia. Society of Neuroscience Abstracts, 21, 1, 825.